Pathomechanism of MicroRNA-29 in Shoulder Stiffness
2 other identifiers
interventional
50
1 country
1
Brief Summary
The team integrates experimental analyses of clinical and basic medicine and transgenic mice models. miR-29a acts a potent protective factor against excessive fibrosis in myofibroblasts of subacromial bursa tissue. Gain of miR-29a stabilizes tendon and synovial tissue homeostasis that alleviates tissue stiffness and maintains function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 13, 2015
CompletedFirst Posted
Study publicly available on registry
August 27, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2019
CompletedFebruary 7, 2017
February 1, 2017
5 years
April 13, 2015
February 5, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The microRNA expression, mRNA expression as a measure
Differences among incidence, microRNA expression, mRNA expression of shoulder stiffness are analyzed using non-parametric student's t-test. P value of \< 0.05 is considered statistically significant.
48hr
Study Arms (2)
miR-29a precursor oligonucleotide
EXPERIMENTALEffects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
miR-29a antisense oligonucleotide
EXPERIMENTALEffects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
Interventions
Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
Eligibility Criteria
You may qualify if:
- aged 18 to 80 years
- receiving surgery for open acromioplasty
You may not qualify if:
- shoulder disorders caused by traumatic fracture
- previous surgery
- osteoarthritis
- malignant disorders
- hepatic disorders
- renal disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chang Gung Memorial Hospital
Kaohsiung City, 833, Taiwan
Study Officials
- PRINCIPAL INVESTIGATOR
Yang-Jih Ko, MD
Chang Gung Memorial Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Double-blind
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 13, 2015
First Posted
August 27, 2015
Study Start
August 1, 2014
Primary Completion
July 31, 2019
Study Completion
July 31, 2019
Last Updated
February 7, 2017
Record last verified: 2017-02
Data Sharing
- IPD Sharing
- Will not share